NEW YORK (GenomeWeb News) – Compugen today said that Teva Pharmaceutical industries has exercised its option to utilize in its research activities a combination of biomarkers discovered by the firm for early detection of drug-induced nephrotoxicity.

The biomarkers were discovered under a collaboration between the two firms in 2007. Compugen used its computational tools, discovery engines, and nucleic acid testing platforms, as well as data from Teva, in a preclinical study.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.